long-term data in men on active surveillance (AS) for prostate cancer. This analysis attempted to define the safety of T therapy in this population.
INTRODUCTION AND OBJECTIVES:
Multiple studies have assessed the risk between hypogonadism (HG) and cardiovascular disease (CVD). Insurance claims data capture care across multiple clinical and inpatient settings giving a more complete picture than can be found in single clinic data. Here we utilize a national claims database to examine the association between diagnoses of HG and CVD.
METHODS: We analyzed subjects from the IBM MarketScan insurance claims database for 2005, 2008, 2010, 2012, and 2014 . Men with HG diagnoses were identified using diagnosis (ICD-9) code, and were matched based on age, year of presentation, and percent with relevant comorbidities, to control men without a diagnosis of HG in a 1:30 ratio. Association between HG, other diseases, and medications was assessed using chi-squared and a Benjamini-Yekutieli adjustment was applied to decrease the false discovery rate.
RESULTS: A total of 65,584 men with a diagnosis of HG and 1,967,520 men without a diagnosis of HG were included. The groups were matched by average age (49.7 years); percent hypertension, hyperlipidemia, and diabetes; and percent with history of heart attack (Table 1A) . Overall, an increased risk of death was observed in men with HG (OR: 2.01; CI: 1.95-2.08), but a decreased risk of heart disease, atherosclerosis, cardiac dysrhythmias, cardiac conductive disorders, congestive heart failure, or ischemic stroke was observed in men with HG (Table 1B) . Diagnoses of erectile dysfunction (OR: 6.15) and testosterone use (OR: 16.7) were included as comparative controls.
CONCLUSIONS: Men with HG have an increased mortality risk, but this does not appear to be due to an increased CV risk in these men. In this large population of men with HG and age and co-morbidity matched controls, we find that HG may be associated with lower risk of CVD. 
The aim of the study was to evaluate the long-term (48 months follow-up)outcomes of pelvic floor muscle (PFM) rehabilitation in males suffering from lifelong premature ejaculation (PE). The patients were all investigated using intravaginal ejaculatory latency time (IELT) and the self-report PrematureMETHODS: A total of 216 participants were retrospectively reviewed in this study, with 174 completing the training protocol. At baseline, all participants had an IELT 60 s and PEDT score >11. Participants completed a 12-week program of PFM rehabilitation, including physio-kinesiotherapy treatment, electrostimulation, and biofeedback, with three sessions per week, with 20 min for each component completed at each session. The effectiveness of intervention was evaluated by comparing the change in the geometric mean of IELT and PEDT values, from baseline, at 3, 6, and 12 months during the intervention, and at 24, 36 and 48 months postintervention, using a paired sample 2-tailed t-test, including the associated 95% confidence intervals.
RESULTS: Of the 174 participants who completed PFM rehabilitation, 151 gained control of their ejaculation reflex, with a mean IELT of 172.9 s and PEDT score of 2.6 at the 12-week endpoint of the intervention, representing an increase from baseline of 41.6 s and 16.0 scores, respectively, for IELT and PEDT (P < 0.0001). Of the 109 participants who completed the 48-month follow-up, 68% and 52% maintained satisfactory ejaculation control at 36 and 48 months post-intervention, respectively. None patients reported side effects.
CONCLUSIONS: To the best of our knowledge, the present study has the longest follow-up period (48 months) reported to date for any intervention for PE. There is a lack of standardized measures to assess improvement following the PFM intervention, with the treatment parameters difficult to define as they are largely based on sensory perception. Nonetheless, there is a continued need for evidence-based research to validate the role of physiokinesiotherapy in the treatment of PE. Although the type, the amount, and the focus (relaxation, strength, support, or control) of exercise required have not yet been standardized, our long-term results suggest that it may be considered as a valid therapeutic option for patients with PE.
Source of Funding: NONE

MP58-17 MONITORING TESTOSTERONE (T) LEVELS IN MEN RECEIVING ORAL TESTOSTERONE UNDECANOATE (TU): DEALING WITH POST-COLLECTION CONVERSION OF TU TO T
Jed Kaminetsky*, New York, NY; Marc Gittelman, Adventura, FL; Ronald Swerdloff, Torrance, CA; James Longstreth, Mundelein, IL; Robert Dudley, Theodore Danoff, Northbrook, IL INTRODUCTION AND OBJECTIVES: Measuring T levels during T replacement therapy is critical to guide dosing decisions. Postcollection conversion of TU to T by esterases in blood from men receiving oral TU can raise measured T levels substantially above actual levels and result in inappropriate titration decisions. We identified a method for T monitoring to address this problem.
METHODS: We evaluated post-collection conversion of TU to T in blood drawn from men who had received a new oral TU and in blood spiked with TU after collection. Blood was collected in Plain, EDTA or NaF-EDTA tubes and then incubated for periods between 0 and 3 hours, at room temperature (RT) or on ice. After incubation, blood was centrifuged and the matrix (serum or plasma) isolated. T and TU concentrations were measured by LC/MS-MS. Regression analysis of rate of changes of T concentration during incubation v. TU concentration was used to develop algorithms to correct for T overestimation. Algorithm accuracy was tested using results from the Phase 3 inTUne Trial of Clarus' oral TU.
RESULTS: T concentrations increase in blood samples containing TU as they await centrifugation. The rate of TU to T conversion depends on TU concentration, incubation temperature, and presence of NaF, an esterase inhibitor. Incubation temperature impacted TU to T conversion the most -rate at RT >5-fold faster than on ice; NaF had less effect than temperature. Most clinic T levels are measured in serum; however, titration in the inTUne Trial of oral TU was based on T in NaF-EDTA plasma. Equations were derived to convert the T concentration measured in one matrix to another. Based on regression analysis of T concentrations in serum and NaF-EDTA plasma, a conversion factor of 1.214 was derived to convert a NaF-EDTA plasma T value to an equivalent serum T value for samples collected 6 hours post-dose (optimal dose-titration sample point for our oral TU). When this conversion factor was tested using T data collected from the inTUne PK visit where both NaF-EDTA plasma and serum were collected, comparing measured serum T values with values derived from plasma T demonstrated a mean error of only 3.1% (N[155; 95% CI 0.4%, 5.8%).
CONCLUSIONS: Post-collection conversion of TU to T can cause overestimation of circulating T levels in men dosed with oral TU. By accounting for the conversion with different tube types / handling conditions, a conversion factor was derived such that T concentrations in our oral TU patients can be monitored using serum T levels. This conversion factor was validated using in TUne data.
Source of Funding: Clarus Therapeutics, Inc.
MP58-18 LARGER THAN LIFE: MOTIVATIONS FOR BODYBUILDING AND ANABOLIC STEROID USAGE
Jonathan Beilan*, Alexander Tatem, Houston, TX; Daniel Mazur, Denver, CO; Jabez Jabez Gondokusumo, Nannan Thirumavalavan, Nelson Vergel, Larry Lipshultz, Houston, TX INTRODUCTION AND OBJECTIVES: Urologists are being called upon to counsel an increasing number of patients who are taking androgenic-anabolic steroids (AAS). Despite the potential negative health ramifications of these drugs, physique competitors have long utilized synthetic testosterone and other anabolic steroids. Although there is great concern regarding the potential side effects of AAS, there has been little research into what drives individuals to start bodybuilding. This study serves to update our previous series in an effort to better understand the motivating factors that prompt individuals to begin both bodybuilding and AAS usage.
METHODS: An online survey was sent to men's health and bodybuilding forums in an effort to target individuals who may be interested in or actively participate in bodybuilding. Answers were anonymous and not linked to personal data in any way. Participants responded voluntarily and were not compensated for their time.
RESULTS: This updated series includes 212 men who responded to the online survey. Of all respondents, 17.9% were 35 years old, 36.3% were between 36-50 years old, and 45.8% were >50 years old. Only 20.3% of men engaged to some degree in bodybuilding/ physique competition, however 77.3% of men were interested in bodybuilding. The most popular motivators for men to bodybuild were enhancing muscle or strength (26.3%), improving appearance (21.1%), and increasing self-esteem (10.5%). A comparison between individuals who currently participate in bodybuilding versus those who are interested to enter the sport revealed similar rates of AAS use (75.8% vs 77.1%, respectively, p[0.17). Furthermore, both of these groups of men have similar rates of non-prescription AAS usage (34.2% vs 25.7%, respectively, p[0.31). Top motivators to start using AAS included seeing positive results in friends (16.0%), enhancing muscle or strength (13.2%), and improving appearance (10.4%).
CONCLUSIONS: Our updated cohort demonstrates that over 75% of men merely interested in bodybuilding use AAS. Remarkably, men interested in bodybuilding have similar rates of non-prescription AAS use compared to those who are already active competitors. Clinicians should remain nonjudgmental and understand that patients interested in bodybuilding are most likely using AAS, and a significant portion of these men are taking non-prescription drugs. We conclude that it is of the utmost importance to take a careful history and consider these motivating factors when evaluating patients for potential hormonal therapy.
